| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 73,023 | 72,971 |
| Net change in cash, cash equivalents and restricted cash | 5,978 | 462 |
| Cash and cash equivalents at beginning of period | 38,266 | - |
| Cash and cash equivalents at end of period | 44,244 | - |
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)